


DATECA databasen

Hvordan går det danske patienter
med testis cancer?


Landsdækkende database for patienter med germinalcelle tumorer (GCC)

- Databasen dækker patienter behandlet i perioden 1984-2007
- Mere end 230 variable er inkluderet og relateret til stadie, prognostiske faktorer, tumor spredning, tumor markører, recidiv etc.
- Samkøring med nationale registre med vital status og dødsårsag for alle patienter frem til November 30, 2012

Landsdækkende database for patienter med germinalcelle tumorer



Landsdækkende database for patienter med germinalcelle tumorer




Patienter stadium I seminom

- 1822 patienter
- Median alder: 36.7 år (range 16-82)
- Median follow up : 15.5 år (range 0-28,8 år)


Recidiver

No. of relapses: 355/1822 (19.5%)




Recidiver

Antal recidiver: 355/1822 (19.5%)




Recidiv - diagnose



Stadie og IGCCCG prognose gruppe ved recidiv (355 recidiver)

Stadie ved recidiv	Antal recidiver (%)
Im	6 (1.7)
Ila	115 (32.4)
Ilb	135 (38.0)
Ilc	75 (21.1)
IIla	13 (3.7)
IIlb	10 (2.8)
God prognose	353 (99.4%)
Intermediær prognose	2 (0.6%)


Recidiver > 60 mdr. (26 ptt.)



18 NED,

★ 3 døde af seminom,
5 døde af andre årsager,

Overlevelse



Sygdoms specifik overlevelse:
99.5 % (15 years)

Død årsager (172 ptt.)

Testis cancer: 6

Behandling: 4


Anden cancer: 57

Andet: 105


Follow up program

[illegible]

Landsdækkende database for patienter med germinalcelle tumorer




82% af recidiver




Stadium I non-seminom recidiver

- 382 recidiver (31%)
- Median tid til recidiv 5 mdr. (range 0-308 mdr.)




2% af recidiver




Stadium I non-seminom recidiv


- Recidiver
 - 71% med forhøjede tumormarkører måned 0-6
 - 60% med forhøjede tumormarkører måned 7-24
 - 32% med forhøjede tumormarkører måned 25+
 - 20% med positiv CT scanning måned 0-6
 - 50% med positiv CT scanning måned 25+



Lokalisering af recidiver




Prognostisk gruppe



- God prognose
- Intermediær prognose
- Dårlig prognose

Overlevelse stadium I non-seminom



Sygdomsspecifik
overlevelse

5 år: 99.5%

10 år: 99.5%

15 år: 99.2%

No. at risk

1226

1169

895


614

374

168

0

Dødsårsager n= 89




- Testis cancer
- Beh. kompl.
- Anden cancer
- Hjerne/kar
- Diabetes
- Infektion
- GI sygdom
- Neurol
- Nyre
- Selvmord
- Misbrug
- Andet

Non-seminom st. I - kontrol efter orkiektomi

ÅR:	År 1												År 2				År 3		År 4		År 5		
MÅNED:	0	1	2	3	4	5	6	7	8	9	10	11	12	15	18	21	24	30	36	42	48	54	60
DATO:																							
Objektiv undersøgelse	○		○		○		○		○		○		○	○	○	○	○	○	○	○	○	○	○
LDH, AFP, HCG	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○	○
Rtg./CT af thorax	○				○				○				○					○					○
CT/MR af abdomen og bækken	○				○				○				○						○				○
S-testosteron, SHBG, frit testosteron, FSH, LH			○														○						○
BT, Faste-kolesterol+BS																	○						○

Bilag 2.

Landsdækkende database for patienter med germinalcelle tumorer




Resultater

Histology	Seminoma		Non-seminoma		
Prognostic Group (%)	Good	Intermediate	Good	Intermediate	Poor
IGCCCG (%)	95	5	66	20	14
5-year OS, % (95% CI)	90	10	56	28	16
IGCCCG, % (95% CI)	95 (92-97)	82 (58-93)	96 (94-97)	89 (85-93)	67 (59-74)
5-year DSS, % (95% CI)	86 Not reported	72 Not reported	92 (90-94)	80 (76-84)	48 (42-54)
	97 (95-98)	85 (61-95)	98 (97-99)	90 (86-93)	71 (63-77)


Fem års OS og DSS med 95% confidens interval (CI).

Resultater




Logrank test: $p=0.887$

OS (A) for seminom patienter og OS (B) for non-seminom patienter
BEP-cohorte




Logrank test: $p<0.001$

Resultater



Logrank test: $p=0.069$



Logrank test: $p<0.001$


DSS (A) for seminom patienter og DSS (B) for non-seminom patienter
BEP-cohorte

Hvad koster det?


Seksualitet

Familie


Arbejde




Nyrefunktion efter behandling



Risk of Cardiovascular Disease after Combination Chemotherapy



Treatment Groups



GCC patients 1984-2007
(N = 5,299)

Patients excluded (n = 440)
GCC-death (n = 226)
Other treatments (n = 164)
Synchronous cancer (n = 50)

Patients eligible for analysis
(n = 4,859)

Surgery
(n = 2,575)


BEP
(n = 1,525)

RT
(n = 694)

RT ↔ BEP
(n = 65)


Multi-variate Analyses

Actuarial rate, 20 years




Cox regression. Adjusted for: Age, tobacco, diabetes and treatment period, MI.

Smoking vs BEP



Cardiovascular Risk



Hvem arbejder:

PhD studerende:

Gry Gundgaard

Jakob Lauritsen

Mette Saksø Mortensen

Ansvarlige:

Niels Holm, Odense

Mads Agerbæk, Århus

Gedske Daugaard, Rigshospitalet